← back to search

Шломо Мелмед

Cedars-Sinai Medical Center · US
Area of research
Endocrinology, Diabetes and Metabolism · Surgery
Research interest
Research interests include Pituitary Gland Disorders and Treatments, Growth Hormone and Insulin-like Growth Factors, Adrenal and Paraganglionic Tumors, and Neuroendocrine Tumor Research Advances.
h-index
112
citations
47,763
works
727
NIH funding
primary concept
Medicine
email

Recent publications

Pathogenesis of Non-Familial Somatotroph Adenomas.
2026cited by 0position: contributordoi
Consensus on acromegaly complications: an update.
2026cited by 0position: contributordoi
Impact of Acromegaly Subtypes on Survival: Results from a Large Multicenter Cohort
Journal of the Endocrine Society 2026cited by 0position: contributordoi
Consensus on acromegaly therapeutic outcomes: an update
Nature Reviews Endocrinology 2025cited by 36position: firstdoi
Consensus on acromegaly therapeutic outcomes: an update.
2025cited by 23position: contributordoi
Pituitary incidentaloma: a Pituitary Society international consensus guideline statement.
2025cited by 18position: contributordoi
Identifying research priorities for pituitary adenoma surgery: an international Delphi consensus statement
Pituitary 2025cited by 8position: middledoi
Pituitary adenomas: biology, nomenclature and clinical classification.
2025cited by 7position: contributordoi
GIP Receptor Antagonism Eliminates Paradoxical Growth Hormone Secretion in Some Patients With Acromegaly.
2025cited by 5position: contributordoi
A broader outlook is required to stage and classify pituitary neoplasms for patient care.
2025cited by 1position: contributordoi
Local Growth Hormone Facilitates Aging of the Colon Epithelial Microenvironment.
2025cited by 0position: contributordoi
Consensus on criteria for acromegaly diagnosis and remission.
2024cited by 98position: contributordoi
A proposed clinical classification for pituitary neoplasms to guide therapy and prognosis
The Lancet Diabetes & Endocrinology 2024cited by 48position: lastdoi
Correction: consensus on criteria for acromegaly diagnosis and remission.
2024cited by 22position: contributordoi
Non-pituitary growth hormone enables colon cell senescence evasion.
2024cited by 8position: contributordoi
Author Correction: Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
2024cited by 3position: contributordoi
Acromegaly Type 1: A Representative Patient.
2024cited by 1position: contributordoi
Reply to 'The shift of therapeutic strategy for prolactinomas: surgery as the first-line option'.
2024cited by 1position: contributordoi
Reply to 'Tumour fibrosis in dopamine agonist-exposed prolactinomas is a diminishing concern'.
2024cited by 1position: contributordoi
Letter to the Editor From Ho and Melmed: Clinical Practice and Nomenclature of Pituitary Neoplasms: Common Sense Must Prevail.
2024cited by 0position: contributordoi
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement
Nature Reviews Endocrinology 2023cited by 329position: lastdoi
Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement.
2023cited by 229position: contributordoi
An individualized approach to the management of Cushing disease.
2023cited by 50position: contributordoi
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers.
2023cited by 45position: contributordoi
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification
Nature Reviews Endocrinology 2023cited by 31position: lastdoi
Pituitary adenoma or neuroendocrine tumour: the need for an integrated prognostic classification.
2023cited by 24position: contributordoi
Treatment of Cushing Disease With Pituitary-Targeting Seliciclib.
2023cited by 23position: contributordoi
Treatment Patterns, Adherence, Persistence, and Health Care Resource Utilization in Acromegaly: A Real-World Analysis.
2023cited by 11position: contributordoi
Non-pituitary GH regulation of the tissue microenvironment.
2023cited by 8position: contributordoi
WIP1 is a novel specific target for growth hormone action
iScience 2023cited by 6position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 49 papers (2019–2026)Maria Fleseriu · Oregon Medical Research Center14 papers (2016–2025) · 8 papers (2021–2025)Monica R. Gadelha · Takeda (Japan)7 papers (2019–2024)John Wass · Georgetown University7 papers (2012–2024)Stephan Petersenn · ERT (Germany)6 papers (2019–2024)Ken K Y Ho · Imperial College Healthcare NHS Trust6 papers (2023–2025)Christian J. Strasburger · Humboldt-Universität zu Berlin6 papers (2012–2020) · 5 papers (2014–2022)Ken K. Y. Ho · Imperial College Healthcare NHS Trust5 papers (2014–2024)David L. Kleinberg · New York University4 papers (2012–2014)Laurence Katznelson · Stanford Medicine4 papers (2019–2024)Alberto M. Pereira · University Vascular Associates4 papers (2019–2025)Anat Ben-Shlomo · Cedars-Sinai Medical Center4 papers (2021–2026)Gérald Raverot · Association pour l'Utilisation du Rein Artificiel dans la région Lyonnaise4 papers (2022–2024)Philippe Chanson · University of Padua4 papers (2012–2024)Felipe F. Casanueva · KU Leuven4 papers (2012–2019)Nienke R. Biermasz · NIHR Cambridge Biomedical Research Centre4 papers (2019–2024)Kevin C.J. Yuen · University of Arizona4 papers (2020–2023)M. Beatriz S. Lopes · University of Virginia Health System3 papers (2022–2024)